NASDAQ

Viking Therapeutics, Inc. (VKTX)

393 Thanks from members

Viking Therapeutics, Inc. (VKTX) exhibits a mix of wider-than-expected quarterly losses driven by heavy R&D investments and strong bullish market sentiment, with analysts highlighting potential upside targets, positive technical momentum, and persistent timeline risks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →